Published in Lancet on May 01, 2010
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev (2011) 2.48
Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ (2011) 1.97
Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis (2014) 1.86
Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation (2011) 1.77
Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals. J Infect Dis (2015) 1.77
Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV (2015) 1.75
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68
Uremia alters HDL composition and function. J Am Soc Nephrol (2011) 1.55
Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov (2011) 1.48
Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol (2011) 1.43
Blood biomarkers of ischemic stroke. Neurotherapeutics (2011) 1.34
Anti-inflammatory therapies for cardiovascular disease. Eur Heart J (2014) 1.28
Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res (2012) 1.28
Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res (2012) 1.11
Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler Thromb Vasc Biol (2013) 1.05
Lysophosphatidic acid in atherosclerotic diseases. Br J Pharmacol (2012) 1.01
Comparative transcriptome analysis of epithelial and fiber cells in newborn mouse lenses with RNA sequencing. Mol Vis (2014) 0.99
Carriage of the V279F null allele within the gene encoding Lp-PLA₂ is protective from coronary artery disease in South Korean males. PLoS One (2011) 0.99
Using hydrogen/deuterium exchange mass spectrometry to define the specific interactions of the phospholipase A2 superfamily with lipid substrates, inhibitors, and membranes. J Biol Chem (2012) 0.96
Sequencing of Lp-PLA2-encoding PLA2G7 gene in 2000 Europeans reveals several rare loss-of-function mutations. Pharmacogenomics J (2011) 0.96
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag (2013) 0.94
Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women. Clin Chem (2012) 0.94
Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review. Lipids Health Dis (2011) 0.93
Lipoprotein phospholipase A2 and cerebral microbleeds in the Framingham Heart Study. Stroke (2012) 0.93
Cardiovascular Disease Risk Assessment: Review of Established and Newer Modalities. Curr Treat Options Cardiovasc Med (2015) 0.92
Osteocalcin positive CD133+/CD34-/KDR+ progenitor cells as an independent marker for unstable atherosclerosis. Eur Heart J (2012) 0.92
Coronary heart disease and genetic variants with low phospholipase A2 activity. N Engl J Med (2015) 0.92
An association study between genetic polymorphisms related to lipoprotein-associated phospholipase A(2) and coronary heart disease. Exp Ther Med (2013) 0.92
Lipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart Study. Diabetes Care (2012) 0.91
Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. Curr Infect Dis Rep (2011) 0.90
Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis. J Am Coll Cardiol (2012) 0.89
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. J Am Heart Assoc (2013) 0.89
Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. Clin Chem (2011) 0.89
Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis. Atherosclerosis (2015) 0.88
Cardiovascular disease risk prediction in women: is there a role for novel biomarkers? Clin Chem (2013) 0.88
Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis (2016) 0.87
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications. World J Cardiol (2015) 0.87
Determination of phospholipase activity of PAF acetylhydrolase. Free Radic Biol Med (2012) 0.87
Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events. Cardiol Ther (2013) 0.86
Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic 'eat-me' signals: cleavage and inhibition of phagocytosis by Lp-PLA2. Cell Death Differ (2014) 0.86
Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women. Am Heart J (2011) 0.85
Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients. Clin Infect Dis (2013) 0.85
Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease. J Am Coll Cardiol (2017) 0.83
Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. PLoS One (2012) 0.82
Biomarkers of cardiovascular disease risk in women. Metabolism (2014) 0.82
Kidney function decline in the elderly: impact of lipoprotein-associated phospholipase A(2). Am J Nephrol (2011) 0.82
Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. Circ Res (2016) 0.81
Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res (2012) 0.81
Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study. Alzheimers Res Ther (2012) 0.81
Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study. Lipids Health Dis (2013) 0.81
Potential serum biomarkers in the pathophysiological processes of stroke. Expert Rev Neurother (2014) 0.81
Inflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application. Front Physiol (2014) 0.81
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc (2016) 0.81
The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care (2013) 0.81
The effect of lipoprotein-associated phospholipase A2 deficiency on pulmonary allergic responses in Aspergillus fumigatus sensitized mice. Respir Res (2012) 0.80
Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection. HIV Med (2014) 0.80
Diabetes and biomarkers. J Diabetes Sci Technol (2011) 0.80
Unraveling the PAF-AH/Lp-PLA2 controversy. J Lipid Res (2014) 0.80
Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study. Atherosclerosis (2014) 0.80
Improvement in stroke risk prediction: role of C-reactive protein and lipoprotein-associated phospholipase A2 in the women's health initiative. Int J Stroke (2012) 0.80
An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib. Br J Clin Pharmacol (2014) 0.80
n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis. Br J Nutr (2013) 0.80
Structural basis of specific interactions of Lp-PLA2 with HDL revealed by hydrogen deuterium exchange mass spectrometry. J Lipid Res (2012) 0.80
Lp-PLA(2) and risk of atherosclerotic vascular disease. Lancet (2010) 0.80
Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study. PLoS One (2014) 0.80
Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients. J Immunol Res (2016) 0.79
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc (2013) 0.79
Lipoprotein-associated phospholipase A₂ activity predicts progression of subclinical coronary atherosclerosis. Diabetes Technol Ther (2011) 0.79
Peripheral artery disease, biomarkers, and darapladib. Am Heart J (2011) 0.79
Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease. Alzheimers Dement (Amst) (2015) 0.79
Racial variation in lipoprotein-associated phospholipase A₂ in older adults. BMC Cardiovasc Disord (2011) 0.79
Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial. PLoS One (2014) 0.79
Assessing gene-environment interactions for common and rare variants with binary traits using gene-trait similarity regression. Genetics (2015) 0.79
Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes. Proc Natl Acad Sci U S A (2016) 0.78
Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers. Lipids Health Dis (2012) 0.78
Leveraging human genetics to guide drug target discovery. Trends Cardiovasc Med (2016) 0.78
Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. Lipids Health Dis (2014) 0.78
Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicability. Dis Markers (2015) 0.77
Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol (2016) 0.77
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids Health Dis (2015) 0.77
Association of Lp-PLA2 Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients. PLoS One (2015) 0.77
Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis? Biomed Res Int (2015) 0.77
Lipoprotein-associated phospholipase A₂ is related to plaque stability and is a potential biomarker for acute coronary syndrome. Yonsei Med J (2014) 0.77
Association of common variants in TOMM40/APOE/APOC1 region with human longevity in a Chinese population. J Hum Genet (2015) 0.77
Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D. J Lipid Res (2014) 0.77
Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles. Eur J Prev Cardiol (2016) 0.77
Association of lipoprotein-associated phospholipase A₂ with characteristics of vulnerable coronary atherosclerotic plaques. Yonsei Med J (2011) 0.77
Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. Atherosclerosis (2015) 0.77
Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways. Biol Open (2015) 0.77
The role of lipoprotein-associated phospholipase A2 in a murine model of experimental autoimmune uveoretinitis. PLoS One (2015) 0.77
Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease. Exp Ther Med (2013) 0.77
Periodontal microbiota and phospholipases: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Atherosclerosis (2015) 0.76
Plasma Lipoprotein-Associated Phospholipase A₂ Levels Correlated with the Cardio-Ankle Vascular Index in Long-Term Type 2 Diabetes Mellitus Patients. Int J Mol Sci (2016) 0.76
Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet (2017) 0.76
Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis. N Am J Med Sci (Boston) (2011) 0.76
Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients. J Am Heart Assoc (2015) 0.76
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet (2007) 15.27
Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med (1991) 12.89
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation (1994) 12.24
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol (1999) 6.42
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med (2000) 3.90
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med (2008) 3.33
Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc (2007) 3.12
Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol (2005) 2.74
Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 2.51
Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol (1994) 2.50
Measures to assess the prognostic ability of the stratified Cox proportional hazards model. Stat Med (2009) 2.23
Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int J Epidemiol (2006) 2.22
Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest (1996) 2.21
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J (1999) 1.92
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet (2009) 1.87
Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis (2000) 1.58
Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest (1997) 1.58
Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke (2008) 1.52
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol (2008) 1.51
Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem (1999) 1.46
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem (2005) 1.40
Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J (2011) 1.23
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet (2008) 1.17
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil (2007) 1.10
Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol (2003) 1.07
Assessment of genetic risk for myocardial infarction. Thromb Haemost (2006) 1.04
Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol (2008) 1.01
Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). J Thromb Haemost (2008) 0.99
Phospholipase A2 inhibitors in atherosclerosis: the race is on. Lancet (2009) 0.89
Description and status of the azithromycin and coronary events study (ACES). J Infect Dis (2000) 0.87
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet (2009) 26.09
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet (2007) 15.27
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 13.69
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology (2005) 13.05
Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med (2014) 12.79
Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet (2008) 12.32
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85
Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med (2003) 10.61
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med (2014) 9.25
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 9.07
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Incidental findings on brain MRI in the general population. N Engl J Med (2007) 8.59
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation (2006) 8.18
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med (2010) 7.83
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Host polymorphisms in interleukin 4, complement factor H, and C-reactive protein associated with nasal carriage of Staphylococcus aureus and occurrence of boils. J Infect Dis (2008) 7.45
Serious mental disorder in 23000 prisoners: a systematic review of 62 surveys. Lancet (2002) 7.43
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2011) 7.30
Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25
Prevalence of serious mental disorder in 7000 refugees resettled in western countries: a systematic review. Lancet (2005) 6.88
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Controlling the risk of spurious findings from meta-regression. Stat Med (2004) 6.80
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet (2010) 6.49
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2011) 6.36
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation (2006) 6.17
Unravelling the fetal origins hypothesis: is there really an inverse association between birthweight and subsequent blood pressure? Lancet (2002) 5.91
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet (2008) 5.89
A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc (2009) 5.81
Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81